Media and Communications

News

2005 News Releases

Friday, December 23, 2005
Teva and IVAX Sign Consent Order, Schedule Anticipated Closing Date for Merger

Jerusalem, Israel and Miami, December 23, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) announced today that, as expected, they have signed a consent order for submission to the U.S. Federal Trade Commission ("FTC") in connection with the pending acquisition of IVAX by Teva. The scope of the consent order is consistent with what the parties have anticipated throughout the FTC review process. Completion of the FTC review process is the last remaining regulatory condition to the consummation of the transaction.Teva and IVAX have scheduled an Read More »

Friday, December 09, 2005
Teva Announces Approval of Cefprozil Tablets and Cefprozil for Oral Suspension Usp

Jerusalem, Israel, December 9, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's ANDAs for Cefprozil Tablets USP, 250 mg and 500 mg and Cefprozil for Oral Suspension USP, 125 mg/5 mL and 250 mg/5 mL. Shipment of these products is expected to commence upon expiry of brand exclusivity later this month. Teva's Cefprozil Tablets and Cefprozil for Oral Suspension are the AB-rated generic equivalents of Bristol-Myers Squibb's broad-spectrum cephalosporin antibiotic Cefzil®.Annual sales Cefzil® T Read More »

Friday, December 09, 2005
Teva Announces Agreement with Cephalon Regarding Settlement of Provigil® Patent Litigation

Parties Also Agree to Business Arrangements Related to Modafinil Jerusalem, Israel, December 9, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Teva Pharmaceuticals USA, Inc. announced today that they have entered into an agreement with Cephalon, Inc. (Nasdaq: CEPH) to settle their pending patent infringement disputes in the United States and the United Kingdom related to PROVIGIL® (modafinil) Tablets [C-IV]. In connection with the settlement, Cephalon will grant Teva a non-exclusive royalty-bearing right to market and sell a generic version of PROVIGIL. Teva's license in the Un Read More »

Wednesday, December 07, 2005
Teva Announces Final Approval of Oxycodone ER Tablets, 10 Mg, 20 Mg and 40 Mg

Jerusalem, Israel, December 7, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Oxycodone Extended Release Tablets, 10 mg, 20 mg and 40 mg. Shipment will begin immediately.Teva's Oxycodone ER Tablets are the AB-rated generic equivalent of Purdue Pharma's Oxycontin® Tablets, a product indicated for the treatment of moderate to severe pain when continuous analgesia is needed for an extended period of time.Total annual sales of the three strengths, including brand and generic Read More »

Wednesday, December 07, 2005
Teva Issues Statement Regarding Outstanding Ivax Convertible Notes

Jerusalem, Israel, December 7, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) issued the following statement regarding the outstanding 1.5% Convertible Senior Notes due 2025 of Ivax Corporation, in connection with Teva's pending acquisition of Ivax.Although it has not made a final decision, and will not do so until following the closing of the acquisition in accordance with the terms of the applicable indenture, Teva does not expect to elect the "public acquirer fundamental change" option with respect to such Notes. This preliminary expectation is subject to change if the Read More »

Monday, December 05, 2005
Teva Announces Final Approval Of Ribavirin Tablets

Jerusalem, Israel, December 5, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Ribavirin Tablets, 200 mg. Shipment of this product will begin immediately.Teva's Ribavirin Tablets are the AB-rated generic equivalent of Roche's Copegus® Tablets, a product indicated for use in combination with peginterferon alfa-2a for treatment of adults with chronic hepatitis C virus who have compensated liver disease and have not been previously treated with interferon alpha.The brand prod Read More »

Friday, December 02, 2005
Teva Announces FTC Will Not File Objections to Effexor® Xr Settlement

Jerusalem, Israel, December 2, 2005 - The Federal Trade Commission has notified Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Wyeth (NYSE:WYE) that it will not file an objection with the United States District Court for the District of New Jersey to the proposed settlement of the patent litigation between Teva and Wyeth concerning Teva's application to market an extended release venlafaxine capsule product. Wyeth markets extended release venlafaxine under the tradename Effexor® XR. Teva and Wyeth will now file motions with the Court requesting that the Court approve the settlement and Read More »

Wednesday, November 30, 2005
Teva Announces Tentative Approval of Zaleplon Capsules

Jerusalem, Israel, November 30, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Zaleplon Capsules, 5 mg and 10 mg. Upon final approval, Teva's Zaleplon Capsules will be the AB-rated generic equivalent of Jones Pharma Inc.'s Sonata® Capsules, a product indicated for short term treatment of insomnia. The brand product has annual sales of approximately $121 million. Teva is currently in patent litigation concerning this product in the U.S. District Court for the District Read More »

Thursday, November 24, 2005
Teva Draws Down on Recently Established US$ 350 Million Syndicated Loan Facility

Jerusalem, Israel, November 24, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has fully drawn down on a US$ 350 multicurrency term loan facility established in September 2005 with a syndicate of banks. The loan is split into two equal tranches of US$ 175 million each, respectively repayable within three and five years. This is the fourth syndicated loan which Teva has put together in the international financial market since 1993.The syndicate was arranged by Sumitomo Mitsui Banking Corporation Europe Limited acting as Facility Agent, together with Citibank, Read More »

Thursday, November 24, 2005
Teva and Ivax Receive European Commission Approval for Acquisition

Jerusalem, Israel, November 24, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and IVAX Corporation (AMEX: IVX) announced today that they received unconditional approval from the European Commission to proceed with Teva's acquisition of IVAX. This European approval completes the non-U.S. regulatory review process, which was required to be completed prior to closing the transaction. Teva and IVAX are continuing to work closely with the U.S. Federal Trade Commission to enable the FTC to complete its review processes shortly.As previously announced, the companies continue to expect tha Read More »

​​​